Works matching IS 13596535 AND DT 2022 AND VI 27 AND IP 1

Results: 13

Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535221083179

By:

Razavi, Homie

Publication type:

Article

Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535221082773

By:

Cihlar, Tomas;
Mackman, Richard L.

Publication type:

Article

Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535221077487

By:

Brown, Dannae;
Kaplan, Richard;
Losso, Marcelo;
Brites, Carlos;
Wang, Ruolan;
Underwood, Mark;
Hopking, Judy;
Aboud, Michael;
Sievers, Jörg

Publication type:

Article

Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211073235

By:

Pierone Jr, Gerald;
Fusco, Jennifer S;
Vannappagari, Vani;
Brunet, Laurence;
Weber, Rachel P;
Aboud, Michael;
van Wyk, Jean;
Ragone, Leigh;
Fusco, Gregory P

Publication type:

Article

Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive treatment for herpesviridae trial.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211072673

By:

Troger, Antoine;
Burrel, Sonia;
Pineton de Chambrun, Marc;
Schmidt, Matthieu;
Bréchot, Nicolas;
Bomme, Olivier;
Hékimian, Guillaume;
Combes, Alain;
Boutolleau, David;
Luyt, Charles-Edouard

Publication type:

Article

Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211067610

By:

Marathe, Gayatri;
Moodie, Erica E M;
Brouillette, Marie-Josée;
Cox, Joseph;
Delaunay, Charlotte Lanièce;
Cooper, Curtis;
Hull, Mark;
Gill, John;
Walmsley, Sharon;
Pick, Neora;
Klein, Marina B

Publication type:

Article

Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211068613

By:

Chiesa, Alessandro F;
Pallanza, Micol;
Martinetti, Gladys;
Lanzi, Fabio;
Previsdomini, Marco;
Pagnamenta, Alberto;
Elzi, Luigia

Publication type:

Article

Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211067589

By:

Abdool Karim, Salim S;
Baxter, Cheryl;
Abdool Karim, Quarraisha

Publication type:

Article

Adefovir for lamivudine-resistant hepatitis B.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211067605

By:

Roediger, Rebecca;
Smyth, Elizabeth Kula;
Dieterich, Douglas

Publication type:

Article

The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211067599

By:

Schinazi, Raymond F;
Patel, Dharmeshkumar;
Ehteshami, Maryam

Publication type:

Article

Tenofovir alafenamide fumarate.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211067600

By:

Lee, William A;
Cheng, Andrew K

Publication type:

Article

The transformation of HIV therapy: One pill once a day.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211062396

By:

Choudhary, Madhu C;
Mellors, John W

Publication type:

Article

Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection.

Published in:

Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211060968

By:

Whitley, Richard J

Publication type:

Article